In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...